Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $48 to $50.
Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?
Famed “Big Short” investor Michael Burry has taken an extremely bearish stance during the third quarter of 2022 — but was it too much?